Periodontal gingipains and Alzheimer’s and Parkinson’s diseases: a review examines the evidence and its limits
Background
A review has examined whether gingipains, protein-degrading enzymes produced by periodontal bacteria, may be involved in Alzheimer’s and Parkinson’s diseases. It synthesizes epidemiological, postmortem brain tissue, cell, and animal studies. It does not establish that gingipains cause either disease in humans or that treatment inhibiting these enzymes slows disease progression.
Published in the International Journal of Biological Macromolecules, the review focuses on gingipains produced by Porphyromonas gingivalis, a bacterium associated with periodontitis. The authors connect gingipain structure and function with evidence related to neurodegeneration and assess the potential of these enzymes as diagnostic markers and therapeutic targets. Understanding the connection between chronic oral inflammation and brain disease requires distinguishing associations observed in patient populations from mechanisms proposed in experimental models.
Key findings
A meta-analysis cited by the review reported associations between periodontitis and Alzheimer’s and Parkinson’s diseases, with odds ratios (ORs) or hazard ratios (HRs) ranging from 1.2 to 3.5. Because this range combines different measures, it should not be interpreted to mean that the probability of developing either disease increases by the same factor for everyone with periodontitis. The supplied abstract does not provide estimates by disease, the number of studies, confidence intervals, or adjustment variables.
Postmortem brain tissue studies reported correlations between gingipain detection and tau and alpha-synuclein pathology, neuroinflammation, and neuronal loss. The abstract describes the detection rate as “over 85–90%,” but does not specify sample sizes by disease, control groups, or detection methods. This figure cannot be applied as a general detection rate across patients with either disease, and detection alone cannot be taken as evidence that gingipains cause disease onset.
Cell and animal models suggest several possible mechanisms. Gingipains may cleave tight-junction proteins between cells, compromising blood–brain barrier integrity, and may trigger glial-cell activation associated with the inflammatory signal NF-κB and the NLRP3 inflammasome. The review also discusses seed formation that initiates amyloid-β and alpha-synuclein aggregation, tau cleavage and hyperphosphorylation, and oxidative damage to mitochondria. These findings do not demonstrate that the same chain of reactions occurs in the same order in the human brain.
Implications and outlook
Salivary gingipain activity has been proposed as a candidate biomarker for noninvasive early risk stratification. The review also mentions the possibility that it could outperform existing fluid biomarkers, but the abstract provides no sensitivity, specificity, or direct comparative results. The available evidence is insufficient to present it as a test that can definitively determine dementia risk in dental practice or replace existing tests.
For treatment development, a key result is that atuzaginstat (COR388) did not meet the primary endpoints in the phase 2/3 GAIN trial. The review says that benefits were reported in a subgroup of participants positive for P. gingivalis, but the abstract does not establish whether the subgroup was prespecified or whether the finding was statistically significant. The next-generation inhibitor LHP588 is described as under development in the phase 2 SPRING trial; no comparative results showing improved efficacy over earlier drugs are provided.
Nanotechnology, CRISPR-based disruption of virulence genes, and targeted delivery technologies are also presented as approaches to improve brain exposure and specificity. The authors emphasize that further biomarker-guided clinical trials are needed to establish causality in humans and determine whether treatment can slow disease progression. The scope and conclusions can be checked in the review abstract.
Chronic periodontitis, driven by Porphyromonas gingivalis, has emerged as a modifiable risk factor for Alzheimer's disease (AD) and Parkinson's disease (PD) the two most prevalent and socioeconomically burdensome neurodegenerative disorders through systemic dissemination of its signature cysteine proteases, gingipains (RgpA, RgpB, Kgp). This narrative critical review is explicitly scoped to AD and PD, the only neurodegenerative conditions for which postmortem detection of gingipains in affected brain regions, mechanistic evidence from cellular and animal models, and clinical epidemiological data currently exist in sufficient depth to support an integrated synthesis. Robust meta-analyses confirm that periodontitis is associated with elevated AD/PD risk (OR/HR 1.2-3.5), while gingipains have been detected in a high proportion (>85-90%) of postmortem AD/PD brains, correlating with tau/α-synuclein pathology, neuroinflammation, and neuronal loss. Mechanistic studies in cellular and animal models demonstrate that gingipains can disrupt blood-brain barrier integrity via tight-junction cleavage, trigger NF-κB/NLRP3-driven glial activation, catalyse amyloid-β/α-synuclein seeding, induce tau truncation/hyperphosphorylation, and precipitate mitochondrial oxidative damage, thereby generating self-amplifying neurotoxic cascades. Salivary gingipain activity offers a non-invasive, high-sensitivity biomarker candidate for early risk stratification that may outperform conventional fluid markers in prodromal cohorts. Therapeutically, small-molecule gingipain inhibitors have shown neuroprotective effects in preclinical models (e.g., atuzaginstat/COR388 failed primary endpoints in the Phase 2/3 GAIN trial but demonstrated subgroup benefits in P. gingivalis-positive participants; the next-generation inhibitor LHP588 is advancing in the Phase 2 SPRING trial). Emerging approaches including nanotechnology, CRISPR-based virulence gene disruption, and targeted delivery platforms aim to improve
The review’s practical value lies in setting out both the rationale for targeting gingipains and the questions that remain untested. Follow-up studies could assess whether salivary gingipain activity is useful for stratifying clinical trial participants and whether clinical outcomes with inhibitors differ between groups classified by that marker. This is one possible application of the biomarker-guided validation proposed by the review. It does not mean that evidence has established that a saliva test alone can definitively determine Alzheimer’s or Parkinson’s disease risk, or that gingipain inhibitors should be administered preventively. During development, target inhibition and actual clinical benefit need to be assessed separately.